Jiangsu Hengrui Pharmaceuticals (600276.SH): SHR-4375 Injection Receives Notice of Approval for Clinical Trial of Medicinal Products

Jiangsu Hengrui Pharmaceuticals (600276.SH) announced that its subsidiary, Suzhou Shengdiya Biopharmaceutical Co., Ltd., has received the approval notice for the clinical trial of SHR-4375 injection from the National Medical Products Administration (referred to as "NMPA"), and will soon start clinical trials. It is reported that SHR-4375 injection is a biopharmaceutical developed by the company, which can specifically bind to tumor cell surface antigens, kill tumor cells, and is intended for the treatment of advanced malignant solid tumors.